Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 386

1.

The pathophysiology of early-stage chronic kidney disease-mineral bone disorder (CKD-MBD) and response to phosphate binders in the rat.

Moe SM, Radcliffe JS, White KE, Gattone VH 2nd, Seifert MF, Chen X, Aldridge B, Chen NX.

J Bone Miner Res. 2011 Nov;26(11):2672-81. doi: 10.1002/jbmr.485.

3.

[CKD-MBD (Chronic Kidney Disease-Mineral and Bone Disorder). Role of FGF23-Klotho axis in CKD-MBD].

Komaba H.

Clin Calcium. 2010 Jul;20(7):1028-36. doi: CliCa100710281036. Review. Japanese.

PMID:
20585181
4.

Interventions for metabolic bone disease in children with chronic kidney disease.

Hahn D, Hodson EM, Craig JC.

Cochrane Database Syst Rev. 2015 Nov 12;(11):CD008327. doi: 10.1002/14651858.CD008327.pub2. Review.

PMID:
26561037
5.

Fibroblast growth factor 23 in hemodialysis patients: effects of phosphate binder, calcitriol and calcium concentration in the dialysate.

Cancela AL, Oliveira RB, Graciolli FG, dos Reis LM, Barreto F, Barreto DV, Cuppari L, Jorgetti V, Carvalho AB, Canziani ME, Moysés RM.

Nephron Clin Pract. 2011;117(1):c74-82. doi: 10.1159/000319650. Epub 2010 Aug 4.

PMID:
20689328
6.

[Either calcium carbonate or sevelamer decreases urinary oxalate excretion in chronic renal failure patients].

Caravaca F, Ruiz AB, Escola JM, Hernández Gallego R, Cerezo I, Fernández N, Barroso S, Martín MV.

Nefrologia. 2007;27(4):466-71. Spanish.

7.

FGF23: its role in renal bone disease.

Fukagawa M, Kazama JJ.

Pediatr Nephrol. 2006 Dec;21(12):1802-6. Epub 2006 Aug 24. Review.

PMID:
16932898
8.

[Effects of intermittent treatment with sevelamer hydrochloride on parathyroid hyperplasia and vascular calcification in rats with chronic kidney disease].

Nagano N, Miyata S, Abe M, Wakita S, Kobayashi N, Wada M.

Clin Calcium. 2005 Sep;15 Suppl 1:35-9; discussion 39-40. Japanese. Erratum in: Clin Calcium. 2006 Feb;16(2):149-52.

PMID:
16272627
9.
10.

Disturbances of Wnt/β-catenin pathway and energy metabolism in early CKD: effect of phosphate binders.

de Oliveira RB, Graciolli FG, dos Reis LM, Cancela AL, Cuppari L, Canziani ME, Carvalho AB, Jorgetti V, Moysés RM.

Nephrol Dial Transplant. 2013 Oct;28(10):2510-7. doi: 10.1093/ndt/gft234. Epub 2013 Aug 23.

PMID:
23975746
12.

Prevention and control of phosphate retention/hyperphosphatemia in CKD-MBD: what is normal, when to start, and how to treat?

Martin KJ, González EA.

Clin J Am Soc Nephrol. 2011 Feb;6(2):440-6. doi: 10.2215/CJN.05130610. Epub 2011 Feb 3. Review.

13.

Sevelamer and the bone-vascular axis in chronic kidney disease: bone turnover, inflammation, and calcification regulation.

Brandenburg VM, Jahnen-Dechent W, Ketteler M.

Kidney Int Suppl. 2009 Dec;(114):S26-33. doi: 10.1038/ki.2009.404. Review.

PMID:
19946324
14.

Fibroblast growth factor 23 production in bone is directly regulated by 1{alpha},25-dihydroxyvitamin D, but not PTH.

Saji F, Shigematsu T, Sakaguchi T, Ohya M, Orita H, Maeda Y, Ooura M, Mima T, Negi S.

Am J Physiol Renal Physiol. 2010 Nov;299(5):F1212-7. doi: 10.1152/ajprenal.00169.2010. Epub 2010 Aug 25.

15.

Effect of RenaGel, a non-absorbed, calcium- and aluminium-free phosphate binder, on serum phosphorus, calcium, and intact parathyroid hormone in end-stage renal disease patients.

Goldberg DI, Dillon MA, Slatopolsky EA, Garrett B, Gray JR, Marbury T, Weinberg M, Wombolt D, Burke SK.

Nephrol Dial Transplant. 1998 Sep;13(9):2303-10.

PMID:
9761513
16.

Interventions for bone disease in children with chronic kidney disease.

Geary DF, Hodson EM, Craig JC.

Cochrane Database Syst Rev. 2010 Jan 20;(1):CD008327. doi: 10.1002/14651858.CD008327. Review. Update in: Cochrane Database Syst Rev. 2015;11:CD008327.

PMID:
20091666
17.

Sevelamer hydrochloride (Renagel), a non-calcaemic phosphate binder, arrests parathyroid gland hyperplasia in rats with progressive chronic renal insufficiency.

Nagano N, Miyata S, Obana S, Ozai M, Kobayashi N, Fukushima N, Burke SK, Wada M.

Nephrol Dial Transplant. 2001 Sep;16(9):1870-8.

PMID:
11522872
18.

Phosphate binders in moderate chronic kidney disease: where do we stand?

Bellasi A, Cozzolino M, Adragao T, Di Iorio B, Russo D.

J Nephrol. 2013 Nov-Dec;26(6):993-1000. doi: 10.5301/jn.5000258. Epub 2013 Mar 25. Review.

PMID:
23543481
19.

Bone health and vascular calcification relationships in chronic kidney disease.

Spasovski GB.

Int Urol Nephrol. 2007;39(4):1209-16. Epub 2007 Sep 26. Review.

PMID:
17899431
20.

Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study.

Brandenburg VM, Schlieper G, Heussen N, Holzmann S, Busch B, Evenepoel P, Vanholder R, Meijers B, Meert N, Fassbender WJ, Floege J, Jahnen-Dechent W, Ketteler M.

Nephrol Dial Transplant. 2010 Aug;25(8):2672-9. doi: 10.1093/ndt/gfq053. Epub 2010 Feb 18.

PMID:
20172849

Supplemental Content

Support Center